APOLLO: Phase 3 randomized study of subcutaneous Daratumumab plus Pomalidomide and Dexamethasone (D-Pd) versus Pomalidomide and Dexamethasone (Pd) alone in patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Authors :: Einsele, H
Dimopoulos, M
Terpos, E
Boccadoro, M
Delimpasi, S
Beksac, M
Katodritou, E
Moreau, P
Baldini, L
Symeonidis, A
Bila, J
Oriol, A
Mateos, MV
Orfanidis, I
Ahmadi, T
Ukropec, J
Kampfenkel, T
Schecter, J
Qiu, Y
Amin, H
Vermeulen, J
Carson, R
Sonneveld, P
Source :: Oncology Research and Treatment, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, instname
Publication Year :: 2021
Publisher :: S. Karger AG, 2021.

ISSN :: 22965262
Database :: OpenAIRE
Journal :: Oncology Research and Treatment, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, instname
Accession number :: edsair.RECOLECTA.....d36df68cc5fd7aed5811fb9dc136a1e2

Tools